Tekla Life Sciences Investors
HQL · NYSE
9/30/2025 | 9/30/2024 | 9/30/2023 | 9/30/2022 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $76 | $0 | $0 | $0 |
| Short-Term Investments | $0 | $17,231 | $15,242 | $0 |
| Receivables | $1,138 | $231 | $5,045 | $623 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $0 | $9 | $0 | -$25 |
| Total Curr. Assets | $1,252 | $282 | $5,045 | $624 |
| Property Plant & Equip (Net) | $0 | $0 | $0 | $0 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $460,301 | $397,529 | $414,076 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $514,130 | $13,901 | $0 | $0 |
| Total NC Assets | $514,130 | $474,203 | $397,529 | $414,076 |
| Other Assets | $0 | -$13,901 | $26 | $25 |
| Total Assets | $515,382 | $460,583 | $402,600 | $414,725 |
| Liabilities | – | – | – | – |
| Payables | $721 | $2 | $0 | $5,100 |
| Short-Term Debt | $0 | $0 | $0 | $11,092 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $5,089 |
| Other Curr. Liab. | $0 | $51 | $0 | -$16,180 |
| Total Curr. Liab. | $721 | $889 | $0 | $5,100 |
| LT Debt | $0 | $0 | $0 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $1,005 | $887 | $667 | $11,723 |
| Total NC Liab. | $1,005 | $887 | $667 | $11,723 |
| Other Liabilities | $0 | $889 | $0 | $6,624 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $1,726 | $889 | $667 | $16,823 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $296 | $281 | $268 | $257 |
| Retained Earnings | $77,604 | $44,128 | -$1,481 | $9,549 |
| AOCI | $0 | $0 | $0 | $0 |
| Other Equity | $0 | $0 | $0 | $0 |
| Total Equity | $513,656 | $459,695 | $401,934 | $397,902 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $515,382 | $460,583 | $402,600 | $414,725 |
| Net Debt | -$76 | $0 | -$0 | $11,091 |